1 | 400 | 400 | 400 | 400 | 400 | 400 | 320 | 320 | 250 | 250 | 250 | 400 | 400 | NA | NA | NA | CF | | 400 | CF | >−6 | CF | | Regressed to dry AMD |
2 | 63 | 40 | 32 | 32 | 32 | 32 | NA | 32 | 32 | 32 | NA | 32 | 40 | 40 | 32 | 32 | | | | 63 | 32 | 3 | 32 | Stabilised PED |
3 | 40 | 63 | 63 | 40 | 63 | 50 | 40 | 40 | 40 | 63 | NA | 50 | 50 | NA | 200 | NA | 100 | 100 | 100 | 40 | 200 | >−6 | 100 | Eccentric recurrence at 82 months |
4 | 250 | 200 | 200 | 400 | 320 | 320 | 320 | 100 | 100 | 400 | 200 | 80 | 80 | 63 | 63 | | | | | 250 | 63 | 6 | 63 | Regressed to dry AMD |
5 | 63 | 63 | 63 | 50 | 50 | 63 | NA | 80 | 63 | 40 | 40 | 50 | NA | NA | 40 | | | | | 63 | 40 | 2 | 40 | Regressed to dry AMD+ |
6 | 400 | 200 | 125 | 100 | 100 | 100 | 160 | NA | 100 | 125 | 200 | 250 | 250 | 640 | NA | NA | CF | CF | CF | 400 | CF | >−6 | CF | Improved but not dry |
7 | 32 | 20 | 16 | 20 | NA | 25 | 25 | 32 | 32 | 32 | 32 | 32 | 63 | 400 | NA | CF | | | 32 | 400 | >−6 | CF | | Regressed to dry AMD |
8 | 40 | 25 | 160 | 250 | 250 | NA | 200 | NA | 200 | 400 | 400 | 400 | CF | NA | CF | CF | CF | CF | 40 | CF | >−6 | CF | | Regressed to disciform scar |
9 | 40 | 40 | NA | 63 | 80 | 500 | NA | NA | NA | CF | NA | 400 | 400 | | | | | | | 40 | 400 | >−6 | 400 | Regressed to disciform scar |
10 | 80 | 100 | NA | NA | NA | NA | NA | 400 | 160 | CF | 160 | 320 | 400 | 200 | 200 | 200 | 320 | | | 80 | 320 | −6 | 320 | Regressed to dry AMD |
11 | 100 | 100 | NA | NA | 100 | NA | NA | NA | NA | NA | NA | HM | HM | | | | | | 100 | HM | >−6 | HM | Vitreous | haemorrhage at 24 months |
12 | 160 | 80 | 63 | 80* | 250* | 200* | 200* | 250* | 250* | 250* | 500* | 400* | 400* | 400* | NA | LP* | | | 160 | 500 | >−6 | LP | | SRN, re-irradiated at 9 months* |
13 | 200 | 100 | 100 | 100 | NA | 63 | NA | 100 | 500 | 200 | HM | CF | NA | CF | CF | CF | | | 125 | HM | >−6 | CF | Vitreous haemorrhage at 36 months | |
14 | 32 | 25 | 20 | 25 | 25 | 20 | 20 | 20 | 20 | 20 | 25 | | | | | | | | | 32 | 25 | 1 | 25 | Regressed to dry AMD |
15 | 50 | 100 | 63 | 100 | 125 | 160 | 200 | 200 | 200 | 250 | 320 | 400 | CF | | | | | | | 50 | 320 | >−6 | CF | TTT given at 36 months |
16 | 32 | 25 | 20 | 20 | 20 | 40 | 20 | 25 | 25 | 40 | 50 | 200 | | | | | | | | 32 | 40 | −1 | 200 | PDT given at 30 months |
17 | 50 | 32 | 32 | 20 | 25 | 50 | 25 | NA | 25 | 32 | | | | | | | | | | 50 | 32 | 2 | 32 | No progression |
18 | 63 | 80 | 125 | NA | NA | NA | 250 | 250 | 250 | 500 | | | | | | | | | | 63 | 500 | >−6 | 500 | Regressed to disciform scar |
19 | 40 | 40 | 40 | 32 | 40 | NA | 50 | 50 | 160 | 320 | CF | | | | | | | | | 40 | 160 | −6 | CF | PDT given at 24 months |
20 | 125 | 100 | 125 | 125 | 200 | 320 | 400 | 200 | 200 | CF | | | | | | | | | | 125 | 200 | −2 | CF | PDT given at 24 months |
21 | 100 | 100 | 100 | 100 | 125 | 125 | NA | 100 | 125 | | | | | | | | | | | 100 | 125 | −1 | 125 | No progression, deceased |
22 | 50 | 63 | 50 | 63 | 100 | 100 | 125 | 250 | 320 | 320 | NA | CF | | | | | | | | 50 | 250 | >−6 | CF | Regressed to disciform scar, deceased |
23 | 32 | 63 | 63 | 100 | 100 | 160 | 200 | 125 | | | | | | | | | | | | 32 | 125 | −6 | 125 | Progressed |
24 | 100 | 100 | 100 | 125 | 125 | 125 | NA | 125 | | | | | | | | | | | | 100 | 125 | −1 | 125 | Regressed to dry AMD |
25 | 160 | 250 | 200 | 200 | NA | NA | 200 | 200 | | | | | | | | | | | | 160 | 200 | −1 | 200 | Improved but not dry, deceased |
26 | 32 | 63 | 80 | 160 | | | | | | | | | | | | | | | | 32 | 160 | >−6 | 160 | Progressed |
27 | 50 | 100 | 160 | 400 | NA | NA | NA | NA | HM | NA | HM | HM | HM | CF | | | | | | 50 | 400 | >−6 | CF | Regressed to disciform scar |
28 | 63 | 50 | 32 | | | | | | | | | | | | | | | | | 63 | 32 | 3 | 32 | Regressed to dry AMD |
29 | 200 | 200 | 320 | | | | | | | | | | | | | | | | | 200 | 320 | −2 | 320 | Progressed, deceased |
30 | 63 | 100 | | | | | | | | | | | | | | | | | | 63 | 100 | −2 | 100 | Lost to follow up |
31 | 125 | 25 | | | | | | | | | | | | | | | | | | 125 | 25 | >+6 | 25 | Lost to follow up |
Mean follow up (months) | | | | | | | | | | | | | | | | 33.3 | | | | | | | | |